These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 5322267)

  • 41. [Urgent problems of antibacterial treatment of pulmonary tuberculosis].
    Pilipchuk NS
    Vrach Delo; 1981 Jan; (1):47-9. PubMed ID: 7010782
    [No Abstract]   [Full Text] [Related]  

  • 42. [Therapeutic experiences with water soluble morphazinamide administered intravenously, by aerosol and topically].
    De Palma M; Mirabelli S; Cinquegrana A
    Minerva Med; 1965 Sep; 56(71):2948-52. PubMed ID: 5322282
    [No Abstract]   [Full Text] [Related]  

  • 43. Chemotherapy of tuberculosis for the 1980's.
    Dutt AK; Stead WW
    Prim Care; 1980 Sep; 7(3):513-27. PubMed ID: 7003628
    [No Abstract]   [Full Text] [Related]  

  • 44. [Intensive chemotherapy of pulmonary tuberculosis].
    Shesterina MV; Gavrilenko VS; Tarasova EF; Sokolova GV; Tregubov IuG
    Probl Tuberk; 1980 Jul; (7):20-22. PubMed ID: 6997865
    [No Abstract]   [Full Text] [Related]  

  • 45. [Clinical experience with morphazinamide].
    Casalone G; Denti F; Rimoldi R
    Minerva Med; 1965 Sep; 56(71):2900-5. PubMed ID: 5322273
    [No Abstract]   [Full Text] [Related]  

  • 46. [CLINICAL AND BACTERIOLOGICAL FINDINGS ON THE USE OF MORPHAZINAMIDE IN THE TREATMENT OF CHRONIC TUBERCULOSIS].
    CERCHIAI E; BELLUOMINI R
    G Ital Chemioter; 1963; 10():74-8. PubMed ID: 14079396
    [No Abstract]   [Full Text] [Related]  

  • 47. [Complex hospital treatment of pulmonary tuberculosis].
    Bondarev IM; Batmanov NIa; Shesterina MV; Gavrilenko VS; Tarasova EF
    Sov Med; 1980; (6):79-82. PubMed ID: 6998023
    [No Abstract]   [Full Text] [Related]  

  • 48. [Therapeutic effects of secondary antitubercular agents at our hospital].
    Nakayama K; Hayashida M; Ishihara M; Ijichi F; Obata Y
    Iryo; 1966 Mar; 20(3):257-63. PubMed ID: 5964832
    [No Abstract]   [Full Text] [Related]  

  • 49. [Experience with te new antitubercular agents isoxyl, ethambutol, morphazinamid and rifomycin].
    Daddi G
    Wien Med Wochenschr; 1967 Mar; 117(11):266-8. PubMed ID: 5626324
    [No Abstract]   [Full Text] [Related]  

  • 50. [Side effects of antibacterial drugs in the clinical course of pulmonary tuberculosis].
    Czkwianianc M; Markiewicz I
    Przegl Lek; 1969 Jun; 25(6):479-81. PubMed ID: 5805095
    [No Abstract]   [Full Text] [Related]  

  • 51. [A comparison of the effects of the combined therapy with CPM+1321 TH+CS, KM+1321 TH+CS and KM+1314 TH+CS in the treatment of pulmonary tuberculosis].
    Iizuka Y; Iwasaki T; Fujioka K
    Kekkaku; 1969 Mar; 44(3):109-15. PubMed ID: 5783307
    [No Abstract]   [Full Text] [Related]  

  • 52. [Evaluation of the therapeutic effects of secondary antitubercular agents].
    Watanabe S; Nosaki M; Iwasaki M; Hamano S; Furuya Y
    Iryo; 1966 Mar; 20(3):251-6. PubMed ID: 5965119
    [No Abstract]   [Full Text] [Related]  

  • 53. [Level of blood serum level of uric acid in tuberculous patients treated with morphazinamide].
    Wawrzeńczyk B; Zaruski A
    Gruzlica; 1973 Feb; 41(2):177-80. PubMed ID: 4695789
    [No Abstract]   [Full Text] [Related]  

  • 54. [Intermittent treatment of pulmonary tuberculosis--controlled clinical trials in Czechoslovakia].
    Víznerová A
    Cas Lek Cesk; 1984 Feb; 123(6):165-9. PubMed ID: 6365321
    [No Abstract]   [Full Text] [Related]  

  • 55. [On the therapeutic use of piazofoline in pulmonary tuberculosis].
    Fici V; Fici G
    Minerva Med; 1966 Dec; 57(101):4375-6. PubMed ID: 5958227
    [No Abstract]   [Full Text] [Related]  

  • 56. [Th 13-14 and PZA and CS in the treatment of chronic cavitary tuberculosis with bacterial resistance to classic antibacterial drugs].
    Zunić D
    Tuberkuloza; 1966; 18(5):429-40. PubMed ID: 16296047
    [No Abstract]   [Full Text] [Related]  

  • 57. [Methods of therapy of patients with chronic destructive pulmonary tuberculosis].
    Utkin VV; Rudoĭ NM
    Klin Med (Mosk); 1968 Dec; 46(12):36-43. PubMed ID: 5737381
    [No Abstract]   [Full Text] [Related]  

  • 58. Results of combined use of cycloserine in pulmonary tuberculosis.
    Tello F
    Scand J Respir Dis Suppl; 1970; 71():162-7. PubMed ID: 5271979
    [No Abstract]   [Full Text] [Related]  

  • 59. [A controlled trial of 6-month and 12-month regimens after negative conversion of sputum in the original treatment of pulmonary tuberculosis. Report of the 21st series of controlled trials of chemotherapy. Cooperative Study Unit of Chemotherapy of Tuberculosis of National Sanatoria in Japan (CSUCTNS)].
    Kekkaku; 1984 Feb; 59(2):81-9. PubMed ID: 6379258
    [No Abstract]   [Full Text] [Related]  

  • 60. [Comparative clinical electroencephalographic study of cycloserine and terizidon tolerance].
    Shmelev NA; Shabalova LN; Kolosovskaia VP
    Antibiotiki; 1975 Feb; 20(2):174-80. PubMed ID: 1091207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.